Neuropace Inc (NPCE) Stock Analysis

Neuropace Inc (NPCE) is a publicly traded company in the HEALTHCARE sector. It trades at $16.29, carries a market capitalization of $563.91M. This page summarizes the public market data, fundamentals, and frequently asked questions for NPCE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NASDAQ

Key Metrics

• Price: $16.29
• Market Cap: $563.91M
• EPS: $-0.65
• 52-Week High: $19.60
• 52-Week Low: $7.56

Market Sentiment

Neuropace Inc currently has a Bullish sentiment score of 0.37.

About Neuropace Inc

NeuroPace, Inc., based in Mountain View, California, is a leader in neuromodulation innovation dedicated to addressing neurological disorders, particularly epilepsy. The company's flagship RNS System delivers responsive brain stimulation to significantly reduce seizures in patients resistant to traditional therapies. As NeuroPace advances its commitment to improving patient outcomes and expands its market reach, it presents a compelling opportunity for institutional investors interested in th...

GNG Research Analysis

GNG Research scores Neuropace Inc (NPCE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NPCE.

Frequently Asked Questions

Does NPCE pay dividends?

Neuropace Inc (NPCE) does not currently pay a regular dividend.

What is NPCE's market cap?

Neuropace Inc (NPCE) has a market capitalization of $563.91M with a current stock price of $16.29.